PuSH - Publikationsserver des Helmholtz Zentrums München

Wester, H.J.* ; Keller, U.* ; Schottelius, M.* ; Beer, A.* ; Philipp-Abbrederis, K.* ; Hoffmann, F.* ; Simecek, J.* ; Gerngross, C.* ; Lassmann, M.* ; Herrmann, K.* ; Pellegata, N.S. ; Rudelius, M.* ; Kessler, H.* ; Schwaiger, M.*

Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging.

Theranostics 5, 618-630 (2015)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Chemokine ligand-receptor interactions play a pivotal role in cell attraction and cellular trafficking, both in normal tissue homeostasis and in disease. In cancer, chemokine receptor-4 (CXCR4) expression is an adverse prognostic factor. Early clinical studies suggest that targeting CXCR4 with suitable high-affinity antagonists might be a novel means for therapy. In addition to the preclinical evaluation of [68Ga]Pentixafor in mice bearing human lymphoma xenografts as an exemplary CXCR4-expressing tumor entity, we report on the first clinical applications of [68Ga]Pentixafor-Positron Emission Tomography as a powerful method for CXCR4 imaging in cancer patients. [68Ga]Pentixafor binds with high affinity and selectivity to human CXCR4 and exhibits a favorable dosimetry. [68Ga]Pentixafor-PET provides images with excellent specificity and contrast. This non-invasive imaging technology for quantitative assessment of CXCR4 expression allows to further elucidate the role of CXCR4/CXCL12 ligand interaction in the pathogenesis and treatment of cancer, cardiovascular diseases and autoimmune and inflammatory disorders.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Korrespondenzautor
Schlagwörter CXCR4; chemokine receptor; positron emission tomography; lymphoma; in vivo imaging; Chemokine Receptor Cxcr4; Acute Myeloid-leukemia; Positron-emission-tomography; Acute Myelogenous Leukemia; Human Cancer Xenografts; B-cell Lymphoma; Antagonist Plerixafor; Myocardial-infarction; Therapeutic Target; Prognostic Value
e-ISSN 1838-7640
Zeitschrift Theranostics
Quellenangaben Band: 5, Heft: 6, Seiten: 618-630 Artikelnummer: , Supplement: ,
Verlag Ivyspring
Verlagsort Lake Haven
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Pathology (PATH)